NCT03896139

Identification of PAthways of Kinase Inhibitors TOxicity

Identification of PAthways of Kinase Inhibitors TOxicity Through Patient Databases

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 4,000 (actual)
• Sponsor: Groupe Hospitalier Pitie-Salpetriere · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.

Conditions

• Kinase Inhibitors Toxicity

Interventions

Type	Name	Description
DRUG	Kinase inhibitor	Patients treated with kinase inhibitors for cancer or other conditions

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-03-01
• Completion: 2019-03-01
• First posted: 2019-03-29
• Last updated: 2019-03-29

Locations

1 site across 1 country: France

Regulatory

• FDA-regulated drug study